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[3H]MPP+ had lower K, and higher V,, values for its accumulation in rat brain synaptosomes than did 
[3H]MPTP. The kinetic parameters favored the uptake of [3H]MPP+ in the striatum to that in hypothala- 
mus, whereas they were equally favorable for the uptake of [3H]MPTP in both regions. Hypothalamic up- 
take of [3H]MPTP and [3H]MPP+ was inhibited by desipramine, imipramine, norepinepbrine, and serotonin. 
Striatal uptake of [3H]MPP+ and [W]MPTP was blocked by nomifensine and dopamine. These results sup- 
port the concept hat MPTP accumulates in serotonergic neurons where it is oxidized by monoamine oxidase 
B to MPP+, which is released and then is selectively accumulated in dopaminergic neurons via the dopamine 
uptake system. 
MPTP MPP+ Neurotoxin 
1. INTRODUCTION 
1-Methyl-Cphenyl-1,2,3,6_tetrahydropyridine 
(MPTP), a nigrostriatal neurotoxin, produces 
parkinsonism in humans [1,2] and nonhuman 
primates [3,4]. The neurotoxicity of this substance 
is thought to be derived from a l-methyl- 
4-phenylpyridinium species (MPP+) [5,6], an 
oxidation product of MPTP which is formed from 
MPTP through a dihydropyridinium intermediate 
(MPDP+) by monoamine oxidase (MAO, EC 
1.4.3.4) [7-111. Pretreatment of animals with the 
MAO B inhibitors, deprenyl and pargyline, effec- 
tively blocks this activation process [5,7,8], as well 
as MPTP-induced dopaminergic neurotoxicity 
[12-141 and the development of parkinsonian 
motor symptoms in primates [8,15]. In contrast, 
the MAO A inhibitor clorgyline has no protective 
effect [7,13]. Hence MAO B is thought to play a 
pivotal role in producing the specific neurotoxicity 
of MPTP. 
+ Visiting Scientist from A. Mickiewicz University, Poz- 
nan, Poland 
Parkinsonism Dopamine uptake 
Javitch et al. [16] reported that mazindol, a 
dopamine uptake inhibitor, was as effective as 
pargyline in preventing MPTP-induced destruction 
of mouse dopaminergic neurons. Furthermore, 
Sundstrom and Jonsson [14] found that amfolenic 
acid, another dopamine uptake blocker, 
counteracted the MPTP-induced reduction of 
mouse striatal dopamine levels. These results sug- 
gest that the neurodegenerative effect of MPTP 
depends not only on its conversion to MPP+ by 
MAO B, but also on the selective uptake of MPP+ 
into nigrostriatal neurons. 
A major unsolved question is the neuronal loca- 
tion of the conversion of MPTP to MPP+. 
Autoradiography of t3H]MPTP binding sites in rat 
brain demonstrated the most intense concentra- 
tions in the arcuate nucleus of the hypothalamus 
(900 fmol/mg), but lower concentrations in the 
substantia nigra (lo-50 fmol/mg) [ 171. These 
high-affinity, saturable and specific binding sites 
correspond to binding sites in rat brain of the 
MAO inhibitor, [3H]pargyline [18]. Javitch and 
Snyder [19] also reported that [3H]MPP+, not 
[3H]MPTP, accumulated into rat striatal synap- 
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tosomes via a dopamine neuronal re-uptake 
system. Selective accumulation of MPP+ in the 
substantia nigra of squirrel monkeys was also 
observed by Irwin and Langston [20]. Collectively, 
these results suggest hat MPTP may be converted 
to MPP+ in neurons outside the striatum or 
substantia nigra. The studies of Sundstrom and 
Jonsson [14] and Uhl et al. [21] implicate non- 
catecholaminergic neurons, while Javitch et al. 
[16] propose that MPP+ originates from 
astrocytes. Direct evidence for the formation of 
MPP+ in specified cell types and export to 
dopaminergic neurons has not yet been reported. 
This paper presents evidence that t3H]MPTP is 
taken up into serotonergic neurons, where it may 
be converted to MPP’ by MAO B, while in con- 
trast, MPP+ is taken up into dopaminergic 
neurons by the dopamine re-uptake system. A 
hypothesis is also presented to explain the selective 
nigrostriatal neurotoxicity of MPTP. 
2. MATERIALS AND METHODS 
l-[methyl-3H]MPTP and l-[methyl-3H]MPP+ 
(acetate) (85 Ci/mmol) were obtained from New 
England Nuclear; and 5-hydroxy-[side chain-Z 
14C]tryptamine creatinine sulphate (56 mCi/ 
mmol), l-[7,8-3H]norepinephrine (32 Ci/mmol) 
and [8-‘4C]dopamine (56 mCi/mmol) from 
Amersham; while MPTP, MPDP+, and MPP+ 
were synthesized in our laboratories [22]. 
Nomifensine maleate, desipramine hydrochloride 
and imipramine were generously supplied by 
Hoechst-Roussel Pharmaceuticals, Hoffman La 
Roche, and Ciba-Geigy, respectively. Other 
chemicals of reagent grade were obtained from 
commercial sources. 
Rat (Sprague-Dawley) striatal and hypothalamic 
synaptosomes were prepared by a modification of 
the method of Gray and Whittaker [23,24]. Synap- 
tosomes were suspended in a medium containing 
50 mM Tris-HCI (pH 7.4), 125 mM NaCl, 5 mM 
KCl, 1 mM CaC12, 1 mM MgCl2 and 10 mM 
glucose (physiological Tris). An incubation mix- 
ture containing radiolabeled compound (50 nM 
[14C]dopamine, 125 nM [i4C]serotonin, 0.25 nM 
[3H]norepinephrine, 0.5 nM [3H]MPTP, 0.5 nM 
[3H]MPP+, 0.02% ascorbic acid and 0.125 mM 
nialamide in physiological Tris was prewarmed 
with or without the test compound at 37’C for 
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5 min. The uptake of radiolabeled compound was 
initiated by addition of freshly prepared synap- 
tosomes (-0.3 mg Pz-protein) and the reaction 
mixture (total volume 1 ml) was incubated at 37°C 
for an additional 5 min (striatal uptake) or 10 min 
(hypothalamic uptake for all radiolabeled com- 
pounds except [3H]norepinephrine, which required 
30 min incubation). A parallel study of the 
radiolabeled compound with and without the test 
agent was carried out at 0°C (ice bath) and the 
values subtracted from those obtained at 37°C to 
obtain active uptake values [25]. In routine uptake 
studies, values of non-P2 blanks (assays without 
Pz-fractions at 37°C) were treated as controls and 
subtracted from the test values, because they were 
indistinguishable from blank values obtained by 
incubation at 0°C. The kinetic parameters (Km and 
I’,,) of uptake were calculated from substrate 
saturation data and I& values from drug inhibi- 
tion isotherms. Protein content of the Pz-fractions 
was determined by the method of Lowry et al. [26]. 
3. RESULTS 
The half-maximal uptake (Km values) of 
[3H]MPP+ into striatal and hypothalamic synap- 
tosomes were 27 and 71%, respectively, of those 
for [3H]MPTP uptake (table 1). The K,,, value for 
the uptake of [3H]MPP+ in striatum was one-half 
of that in hypothalamus. These results indicate 
that rat brain synaptosomes have a greater affinity 
for MPP+ than for MPTP, and that MPP+ is more 
likely to accumulate in striatum than in 
hypothalamus. In striatum, the Km value for 
[‘H]MPP+ was approx. 40% of that for 
[14C]dopamine. In hypothalamus, the K,,, value for 
t3H]MPTP was approx. 88% of the K, for 
t3H]norepinephrine, but was 4-fold of that for 
[14C]serotonin. These data suggest that MPP+ may 
compete with dopamine uptake in striatum, while 
MPTP may compete with norepinephrine uptake 
in hypothalamus. 
The maximal rates of uptake (I’,,,, values) of 
[3H]MPP+ in both brain regions were approx. 
3-5-fold higher than those observed for 
t3H]MPTP (table 1). The Vmax for uptake of 
[3H]MPP+ in striatum was approx. 2-fold of that 
in hypothalamus, whereas the Vmax for uptake of 
t3H]MPTP in striatum was only approx. 40% 
higher than that in hypothalamus. Compared to 
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Table 1 
Kinetic parameters of the uptake of radiolabeled biogenic amines, 
MPTP, and MPP+ in rat brain synaptosomes 
Radiolabeled 
compound 
Brain 
region 
V 
bKi) (pmo;JYnin 
per mg) 
[3H]MPTP striatum 0.73 1.38 
hypothalamus 0.58 0.99 
[3H]MPP+ striatum 0.20 7.35 
hypothalamus 0.41 3.28 
[ 14C]Dopamine striatum 0.49 42.78 
hypothalamus 0.24 6.58 
[3H]Norepinephrine striatum 0.21 5.27 
hypothalamus 0.66 7.59 
[r4C]Serotonin striatum 0.19 9.57 
hypothalamus 0.13 4.35 
All radiolabeled compounds (0.05-0.8 pM) were incubated at 37°C 
for 5 min (striatal uptake) or 10‘min (hypothalamic uptake) with 
approx. 0.3 mg of freshly prepared Pz-fraction in physiological Tris 
containing 0.02% ascorbic acid and 0.125 mM nialamide. Control 
samples were incubated in the absence of the Pz-fraction. See section 
2 for experimental procedures. Km and V,,,., values were obtained by 
plotting the reciprocal of the uptake velocity vs the reciprocal of the 
concentration of the radiolabeled compound 
the V,, values for uptake of biogenic amines in 
striatum, the rate of [3H]MPP+ uptake was 17, 139 
and 77% of those for [t4C]dopamine, 
t3H]norepinephrine and [r4C]serotonin, respective- 
ly. Similarly, the vmax value for uptake of 
[3H]MPTP in hypothalamus was 15, 13 and 23% 
of those for [r4C]dopamine, j3H]norepinephrine 
and [14C]serotonin, respectively. These results in- 
dicate that V,, values for uptake of [3H]MPP+ 
and [3H]MPTP in rat brain synaptosomes are 
generally lower than the corresponding rates of up- 
take of biogenic amines. 
Tables 2 and 3 present results from an extensive 
series of studies on the inhibition by drugs of the 
uptake of radiolabeled MPTP, MPP+ and 
biogenic amines in rat striatal and hypothalamic 
synaptosomes. Nomifensine, a dopamine uptake 
blocker, and dopamine more effectively inhibited 
the uptake [3H]MPP+ than the uptake of 
[3H]MPTP in striatal synaptosomes (table 2). 
Table 2 
Inhibition of the uptake of [‘4C]dopamine, [‘H]MPTP 
and [3H]MPP+ into rat striatal synaptosomes 
Compound IGo, PM 
[14C]Dopamine [‘HIMPTP [3H]MPP+ 
Dopamine 0.51 1.80 0.03 
Nomifensine 0.08 0.45 0.04 
MPP+ 0.43 0.13 0.02 
MPTP 5 2 6 
MPDP+ 13 2.5 0.22 
Radiolabeled compounds (50 nM [14C]dopamine, 
0.5 nM [3H]MPTP and 0.5 nM [3H]MPP+ were 
incubated with at least 6 concentrations of the test agent 
in the presence of freshly prepared striatal synaptosomes 
(-0.3 mg). The amounts of the active uptake of the 
radiolabeled compound into synaptosomes were 
calculated and plotted against the concentrations of the 
test agent to obtain the I& values. Values presented are 
the mean of duplicate assays 
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Table 3 
Inhibition of the uptake of [r4C]serotonin, [3H]norepinephrine, [3H]MPTP and 
[3H]MPP+ into rat hypothalamic synaptosomes 
Compound IGo, /M 
[14C]Serotonin [3H]Norepinephrine [3H]MPTP [3H]MPP+ 
Serotonin so.1 7.2 3.7 3.5 
Norepinephrine 522.5 0.16 1.4 SO.5 
Desipramine 23.5 5 0.0035 0.088 0.0015 
Imipramine 0.25 5 0.032 0.13 0.011 
MPTP 1.5 1.2 0.80 0.23 
MPDP+ 87 0.80 0.13 0.58 
MPP+ 12.5 0.22 0.35 0.14 
Radiolabeled compounds (125 nM [14C]serotonin, 0.25 nM [3H]norepinephrine, 
0.5 nM [3H]MPTP and 0.5 nM [3H]MPP+) were incubated with the test agent and 
hypothalamic synaptosomes (-0.3 mg). I& values were obtained from the drug 
inhibition isotherms (see table 2). Values presented are the mean of duplicate assays 
These 2 drugs also inhibited the striatal uptake of 
[14C]dopamine, but with less potency. Table 3 
shows that desipramine, a norepinephrine uptake 
blocker, was the most effective blocker of the up- 
take of both [‘H]MPTP and [‘H]MPP+ in 
hypothalamus. Imipramine, a serotonin and 
norepinephrine uptake blocker, also inhibited the 
accumulation of tritiated MPTP and MPP+ in 
hypothalamus, but with no more than 68% of the 
potency of desipramine. Norepinephrine and 
serotonin inhibited hypothalamic uptake of 
[3H]MPTP and [3H]MPP+ with 1% values at the 
PM range (16% of the potency of desipramine). 
Table 3 also shows that the 1Cs0 values obtained by 
those 7 compounds are generally lower for 
[3H]MPP+ uptake than for [3H]norepinephrine 
and [14C]serotonin uptake in the hypothalamus. 
4. DISCUSSION 
Although MPTP must be converted to MPP+ by 
MAO B to become cytotoxic [5-151, the basis of 
the selective nigrostriatal neurotoxicity of this 
compound remains unknown. The present finding 
of serotonergic conversion of MPTP to MPP+ and 
dopaminergic accumulation of MPP+ provides a 
model to explain the selective neurodegenerative 
effect of MPTP. Fig.1 summarizes our hypothesis, 
which is based on data from the rat brain synap- 
tosomal system. 
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We propose that MPTP accumulates in the 
striatum and hypothalamus at equal rates. The ac- 
cumulation of MPTP in the hypothalamus 
probably occurs via norepinephrine and serotonin 
re-uptake systems, because desipramine, im- 
HYPOTHALAMUS 1 MPP+ 1 STRIATUM 
Deslpramme 
lmipramme 
MPP+ 
Pargylme 
Norepmephrine 
Serotonm 
Fig.1. Hypothetical mechanism for serotonergic 
conversion of MPTP and dopaminergic accumulation of 
MPP+. MPTP is accumulated into hypothalamic and 
striatal neurons at equal rates. Once inside the 
serotonergic neurons, MPTP is oxidized by MAO B to 
MPP+, which may be released into interneuronal spaces. 
MPP+ is then specifically accumulated into 
dopaminergic neurons in striatum, where it induces 
neurodegeneration. At the same time, the MPTP and 
MPP+ which accumulate in the striatum could inhibit 
MAO A, elevating dopamine to neurotoxic levels. 
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ipramine, norepinep~ine, and serotonin are po- 
tent inhibitors of this process. Since hypothalamus 
is rich in serotonergic neurons or terminals [27,28] 
which contain MAO B [29,30], MPTP may be con- 
verted to MPP’ via MPDP+ in these neurons. 
MPP+ (or MPDP+) may be released from 
serotonergic neurons and/or astrocytes into the in- 
terneuronal spaces, which then carry it to 
dopaminergic neurons. The hypothalamic release 
of t3H]MPP” may be a reversal of its uptake. If so, 
this process is approx. 3-fold faster than the up- 
take of [3H]MPTP and may be equivalent o 43% 
of the uptake of norepinephrine or 75% of the up- 
take of serotonin. Such spontaneous release of 
MPP+ from serotonergic neurons could explain 
their relative invulnerability to MPP+ neuro- 
toxicity. 
Newly synthesized and released MPP+ may then 
be specifically transported into the striatum. Since 
this process is selectively blocked by dopamine and 
nomifensine (ICSO = 0.03-O.O4pM), this uptake 
may occur via the dopamine re-uptake system, as 
proposed by Javitch et al. [16], Sundstrom and 
Jonsson [14], and Uhl et al. [21]. Once in the 
striatum, MPP+ (or MPDP+) and MPTP could in- 
hibit MAO A activity [31,32] and thus elevate 
dopamine to neurotoxic levels [33], although other 
toxic mechanisms could also account for the 
striatal cell destruction observed. 
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